AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04372238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard OEND
Description: In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
Study NCT04372238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard OEND
Description: In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
Study NCT04619407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: SARS-CoV-2 PCR
Study NCT04619407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
Study NCT03707561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months
Study NCT04101890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diaper care with Theraworx
Description: Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
Study NCT04101812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
Study NCT04101812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1
Description: PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
Study NCT04101812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
Study NCT04191668 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl
Description: The NightOwl is a finger-mounted home sleep apnea testing device
Study NCT03397186 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03397186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03397186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trabectedin
Description: Given as standard of care
Study NCT01760434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Long-term outcomes
Description: Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
Study NCT01887912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile Toxoid Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01887912 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 0.9% normal saline
Description: 0.5 mL, Intramuscular
Study NCT06556108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALPP CAR-T cells
Description: T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
Study NCT06556108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT06556108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT04199923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single leg immobilisation
Description: Immobilisation with single leg suspension immobilisation
Study NCT03815292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-MAP
Description: Oral administration
Study NCT03815292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT02241486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Fentanyl Spray
Description: Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
Study NCT01934504 — intervention group
Intervention type: PROCEDURE
Intervention: Venipuncture for blood sample collection
Description: Analysis samples from the blood sample collection at specific time points.
Study NCT00277537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 320mg BD 12 weeks followed by 40 weeks open label
Study NCT00277537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: BD for 12 weeks
Study NCT03771625 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: whole brain with/without spinal cord
Study NCT02141061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation A
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transperineal prostate biopsy
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transrectal prostate biopsy
Study NCT01315821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 5 million units/day for 3 months
Study NCT02224742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LeucoPatch
Description: LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
Study NCT02224742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~* Formal assessment of ulcer and surrounding skin~* Provision of any necessary off-loading~* Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~* Appropriate dressing products~* Appropriate antibiotic therapy~* Nutrition and self care~* Optimal glycaemic control~* Revascularisation if deemed clinically necessary~* Continued close observation
Study NCT03083886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care
Description: Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
Study NCT03083886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Postural Therapy (IPT) + PCP led care
Description: IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
Study NCT03083886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual PCP led care
Description: Primary care provider will direct patients' care pathway.
Study NCT01907334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus100/50 µg
Description: Advair Diskus 100/50 µg
Study NCT02141061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation B
Study NCT03036930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03036930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Undergo self-collection of vaginal/cervical samples
Study NCT03036930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03036930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT03446677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Stability Testing
Description: Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
Study NCT02427061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program (Manhood 2.0)
Study NCT02427061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Program (Job Skills Training)
Study NCT03118622 — intervention group
Intervention type: DEVICE
Intervention: Pentax
Description: Intubation using Pentax video laryngoscope in Pentax group
Study NCT00345605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
Study NCT00345605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
Study NCT03467620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
Study NCT03467620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of one oral placebo capsule daily for a duration of 12 weeks
Study NCT03538028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered as an intravenous infusion over 30 minutes.
Study NCT02210780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administered via subcutaneous injection.
Study NCT02210780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance containing no medicine administered via subcutaneous injection.
Study NCT03360929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
Study NCT03339141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation position
Description: The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
Study NCT01907334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus 100 µg
Description: Flovent Diskus 100 µg
Study NCT01907334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
Study NCT01907334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol will be administered at the end of each methacholine challenge.
Study NCT04175366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Shared Decision Making including adapted decision aid.
Study NCT03284476 — intervention group
Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: Medical data collected on a electronic secured data base
Study NCT03978923 — intervention group
Intervention type: DEVICE
Intervention: preparation of the implant site with Piezosurgery vs drill
Description: The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0.
Study NCT02622737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
Study NCT02622737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary bike
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
Study NCT02622737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
Study NCT00056667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation response and cognitive behavioral therapy
Description: The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
Study NCT00056667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation response
Description: The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
Study NCT00056667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RA education
Description: RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
Study NCT02957318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FiberBind
Description: Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
Study NCT02957318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RG-I fiber
Description: Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
Study NCT02957318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low-fiber control
Study NCT03649477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.2 mg intranasal carbetocin
Description: three times per day with meals
Study NCT03649477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.6 mg intranasal carbetocin
Description: three times per day with meals
Study NCT03649477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three times per day with meals
Study NCT05070052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 9 sessions of CBT weekly treatment in group setting
Study NCT05070052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based cognitive therapy
Description: 9 sessions of MBCT weekly treatment in group setting
Study NCT02005419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02005419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02005419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02005419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.